Cell Reports (Apr 2024)

A platform for predicting mechanism of action based on bacterial transcriptional responses identifies an unusual DNA gyrase inhibitor

  • Shawn French,
  • Amelia Bing Ya Guo,
  • Michael J. Ellis,
  • Julia P. Deisinger,
  • Jarrod W. Johnson,
  • Kenneth Rachwalski,
  • Zoë A. Piquette,
  • Telmah Lluka,
  • Miranda Zary,
  • Sineli Gamage,
  • Jakob Magolan,
  • Eric D. Brown

Journal volume & issue
Vol. 43, no. 4
p. 114053

Abstract

Read online

Summary: In the search for much-needed new antibacterial chemical matter, a myriad of compounds have been reported in academic and pharmaceutical screening endeavors. Only a small fraction of these, however, are characterized with respect to mechanism of action (MOA). Here, we describe a pipeline that categorizes transcriptional responses to antibiotics and provides hypotheses for MOA. 3D-printed imaging hardware PFIboxes) profiles responses of Escherichia coli promoter-GFP fusions to more than 100 antibiotics. Notably, metergoline, a semi-synthetic ergot alkaloid, mimics a DNA replication inhibitor. In vitro supercoiling assays confirm this prediction, and a potent analog thereof (MLEB-1934) inhibits growth at 0.25 μg/mL and is highly active against quinolone-resistant strains of methicillin-resistant Staphylococcus aureus. Spontaneous suppressor mutants map to a seldom explored allosteric binding pocket, suggesting a mechanism distinct from DNA gyrase inhibitors used in the clinic. In all, the work highlights the potential of this platform to rapidly assess MOA of new antibacterial compounds.

Keywords